ejpmr, 2021,8(6), 294-300

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Research Article

ISSN 2394-3211

EJPMR

ENHANSEMENT OF SOLUBILITY OF DESLORATADINE BY USING SUITABLE POLYMERS

Dhiraj Kumar[1*], Vandana Singh[1] and Dr. Shamim Ahmad[1]

Translam Institute of Pharmaceutical Education and Research, Meerut, India.

***Corresponding Author: Dhiraj Kumar**

Translam Institute of Pharmaceutical Education and Research, Meerut, India.

Article Received on 29/03/2021 **Article Revised on 19/04/2021** **Article Accepted on 09/05/2021**

ABSTRACT

Desloratidine is a weakly aqueous, dissolvable antihistamine medicate, which has a place with the BCS class II. The impact of hydrotropes, for example, sodium benzoate, urea, sodium salicylate, sodium acetic acidsodium citrate, derivation and nicotinamide on the dissolvability of desloratidine was inspected. The medication is broken up in several hydrotropic products with 1 to 6 M and .max is calculated using the UM-visible spectrum. The solvency of the medication was observed to be 0000559 mg/ml, showing that the medication is once in a while dissolvable. Accordingly, the expansion of hydrotropic operators expanded the dissolvability of the medication. The dissolvability improvement ratios of varioushydrotropes can be classified in slow order as: sodium salicylate> sodium benzoate>nicotinamide> sodium acetate> sodium citrate> urea. From the outcomes of the dissolving focuses, UV and FTIR checks, it very well may be inferred that the medicine is unadulterated and has no pollutions.The expression of the saturated drug (35%) of sodium salicylate at 50 minutes and that of sodium benzoate was (25%) and was (15%) in nicotinamide, indicating that the results agree with the solvency. From the different arrangements of the hydrotropic strategy, it was inferred that the most extreme grouping of hydrotropic specialists demonstrated the best outcomes with this system. The method is simple and can be used in the laboratory on a smaller scale.

INTRODUCTION

SOLUBILITY SIGNIFICANCE

Solubility improved technique can be ordered for physical changes, substance changes in medication excipient's and other method. Physical changes are molecule size decrease like micronization and nano suspension, changes of the gem structure like polymorphs, indistinct structure and crystallization, tranquilize scattering in bearer like eutectic blend, strong scatterings, strong arrangement and cryogenic technique. Chemical changes like changing of pH, utilization of cushion arrangement, derivatization, complexation, and salt formation. Other strategies that are Supercritical liquid procedure, utilization of adjuvant surfactants, dissolvability, hydrotropic operators and novel excipient. They can expand the fluid dissolvability for expanding the viability and lessening the reactions of the medication. This has been genuine for parenteral, topical and oral managed details. Hydrotropy was one of the solvencies upgrading strategy which increment dissolvability by utilizing the hydrotropic operators like Sodium benzoate, Sodium citrate, Urea, Niacin amide and so on and have many advantage that it doesn't require concoction changes of hydrophobic medications, utilization of natural dissolvable, orpreparation of emulsion solutionetc.

MATERIAL AND METHOD

1. Identification of drug

1.1 Determination of Melting point: Anopenend capillary tube was taken and Desloratadine, drug will be filled in it and record the temperature at which the drug will start melting by Digital melting point apparatus.

1.2 UV analysis of drug identification: There will be studied λ_{max} of Desloratadine drug by UV-visible spectrophotometer.

1.3 Determination of functional groups by FTIR: Functional groups will be determined by the spectrum of FTIR Spectrophotometer for the identification of Desloratadine Drug.

1.2 Analytical Methods

1.2.1 Scanning of Drug: The drug is saturated with water and then the solution is scanned to found the λ_{max} of the drug.

1.2.2 Preparation of Standard Plot of drug: The drug is being dissolved in different medium such as 0.1N HCl, Methanol and water with various concentrations and the λ_{max} is being estimated utilizing UV-visible spectrophotometer. Now the solution is sonicate for 15 minutes and then solution is filtered through the

Whattmann filter paper/41.The reading were calculated in triplicates and mean and standard deviation was noted down. Using these values we will further calculate the solubility of the drug in various hydrotropic agents.

1.4 Preformulation studies

1.3.1Determination of Solubility of the Drug: The medication solvency of the medication is resolved at 25±1ºC and now the medication is added to the two screws topped 10ml of volumetric flask containing distinctive watery frameworks, for example, refined water and diverse hydrotropic specialists. The volumetric cups were shaken precisely for 12h at 25+1ºC in a Sonicator. These arrangements were permitted to equilibrate and the supernatant fluid was taken for proper weakening in the wake of sifting through Whitman channel paper and broke down spectrophotometrically against water as clear. It was seen that there is augmentation in the solvency of the medication in different hydrotropic specialists.

1.4 Formulation of Hydrotropes

1.4.1 Determination of Solubility in different hydrotropic agents: Solubility of the drug is decided at 28± 2.in which abundance measure of the medication was added to the 25ml volumetric flagon containing 15ml of various watery framework viz. refined water, sodium benzoate(1,2,4,6,8M),Urea(1,2,4,6,8,10M) and sodium acetate(1,2,4,6,8 M) and arrangement and so on. The upgrade proportion in solvency was controlled by the accompanying recipe:

Solvency of the medication in hydrotropic arrangement/Solubility of the medication in refined water (mg/ml).

1.4.2 Preparation of the hydrotropic solution: The medication is being broken down in the different hydrotropic operator containing distinctive fixation and the model was moved into 50ml volumetric flagon including diverse convergence of the medication and the arrangement is being shaken, sonicate for the 7min and weakened up to 50ml with refined water and sifted through the Whitman channel paper#1 and of the separated arrangement was extra weakened to 50ml with refined water to figure stock arrangement (100mg/ml).

1.4.3 Selection of Hydrotropes: Distinctive accessible hydrotropic solubilizer including refined water, sodium benzoate(1,2,4,6,8M), Urea(1,2,4,6,8,10 M) and sodium acetic acid derivation (1,2,4,6,8 M) are being utilized for improvement at room temperature.

1.4.4 Properties of the Hydrotropes: The various solution properties of hydrotropesuch pH, conductance wasalsobeing studied to raise the solubility of the drug with increase in the hydrotropic concentration.

1.5 Evaluation of Hydrotropy

1.5.1 Determination of Conductance: Conductance was being determined by calibration against 0.1M KCl. The various hydrotropic solutions were made and conductance values were noted down with respect to each hydrotropic agent.

1.5.2 Determination of pH: Using the digital pH meter, the various hydrotropic solutions were measured at various concentrations.

1.5.3 UV Spectral Studies: UV scanning was performed for Desloratadine in various hydrotropic agents and in water. The Water: Methanol (1:1) is used as stock solution and further dilution is done with the concentration range of 4-20µg/ml to estimate the absorbance of Desloratadine the UV-visible spectrophotometer in the range of 200-400nm.The various hydrotropic solutions was also scanned under UV-visible spectrophotometer using water as a blank reagent in the range of 200-400nm.

1.5.4 FTIR Scanning: FTIR scan of drug and various hydrotropic solutions was recorded from 4000cm^{-1} to 400cm^{-1} .This scan is done to check the presence of various functional groups in the spectra of drug and various hydrotropic agents.

1.5.5 Cumulative percentage Drug Permeated Study: In this cumulative drug release study we have used the diffusion cell apparatus in which we used phosphate buffer saline (0.1 M, pH=7.4) at 37 C. It consists of receptor as phosphate buffer (pH=7.4) and donor as saturated solution of the drug and various hydrotropic agents. The study was carried for 3hrs and at prearranged time intervals (10, 20, 30, 40, 50…180 min) 1ml aliquots were withdrawn, diluted and analyzed spectrophotometricallyatλmax 247nm.An equal volume of fresh medium, was replaced into the apparatus after each sampling. Permeated study was performed in duplicate for each batch. Drug concentration will be examined by UV visible spectroscopy by dilution of drug sample in different media.

RESULT AND DISCUSSIONS

UV Scanning of Drug (Water: Methanol)



Fig 1: UV Scan of Desloratadine in Water: Methanol.

FTIR Spectroscopy of drug



Fig 2 FTIR of Desloratadine.

Preparation of Standard plot of drug

Standard Plot with Methanol



Fig 3: Standard Plot with Methanol.

FTIR Scanning

Nicotinamide: Interpretation of FTIR spectra of Desloratadine-Nicotinamide.



Fig 4: FTIR spectrum of Desloratadine-Nicotinamide.

Sodium Citrate: Interpretation of FTIR spectra of desloratadine-Sodium Citrate.



Fig 4: FTIR spectrum of Desloratadine-Sodium Citrate.

Sodium Benzoate: Interpretation of FTIR spectra of Desloratadine-Sodium Benzoate.



Fig 5: FTIR spectrum of Desloratadine-Sodium Benzoate.

Table 1: Percentage Cumulative Drug Permeated Study.

Time (min)	Absorbance (nm)								
	A1	A2	Average	Conc (µg/ml)	D.F	Conc (mg/ml)	Conc (mg/ml)*7.5	CDP	%CDP
10	0.023	0.022	0.0225	0.0238	10	0.0000238	0.0001785	0.000179	1.103
20	0.029	0.028	0.0285	0.261	10	0.000261	0.0019575	0.001981	12.24
30	0.03	0.03	0.03	0.321	10	0.000321	0.0024075	0.002692	16.63
40	0.033	0.031	0.032	0.4	10	0.0004	0.003	0.003606	22.28
50	0.037	0.042	0.0395	0.757	10	0.000757	0.0056775	0.006683	41.29
60	0.039	0.043	0.041	0.698	10	0.000698	0.005235	0.006998	43.23
80	0.044	0.049	0.0465	0.976	10	0.000976	0.00732	0.009781	60.43
100	0.049	0.051	0.05	1.115	10	0.001115	0.0083625	0.011799	72.90
120	0.051	0.053	0.052	1.194	10	0.001194	0.008955	0.013507	83.45
180	0.059	0.055	0.057	1.392	10	0.001392	0.01044	0.016186	100



Fig 6: Drug Permeated Study.

Table 2: Percentage Cumulative Drug Permeated in Nicotinamide.

Time (min)	Absorbance (nm)								
	A1	A2	Average	Conc (µg/ml)	D.F	Conc (mg/ml)	Conc (mg/ml)*7.5	CDP	%CDP
10	0.047	0.048	0.0475	1.0158	10	0.0101	0.07575	0.07575	8.43
20	0.054	0.053	0.0535	1.253	10	0.0125	0.09375	0.08585	9.56
30	0.059	0.069	0.064	1.67	10	0.0167	0.12525	0.10845	12.07
40	0.069	0.073	0.071	1.948	10	0.0194	0.1455	0.14775	16.45
50	0.074	0.08	0.077	2.186	10	0.0218	0.1635	0.20645	22.99
60	0.081	0.085	0.083	2.424	10	0.0242	0.1815	0.28695	31.95
80	0.085	0.111	0.098	3.019	10	0.0301	0.22575	0.39165	43.61
100	0.101	0.113	0.107	3.376	10	0.0337	0.25275	0.52645	58.62
120	0.104	0.114	0.109	3.456	10	0.0345	0.25875	0.69495	77.39
180	0.112	0.115	0.1135	3.634	10	0.0363	0.27225	0.89795	100

Percentage Cumulative Drug Permeated in Nicotinamide



Fig 7: Drug Permeated Study in Nicotinamide.

Percentage Cumulative Drug Permeated in Sodium Salicylate

Table 3: Percentage Cumulative Drug Permeated in Sodium Salicylate.

TIME (MIN)	Absorbance								
	A1	A2	Average	Concentration (µg/m)	D.F	Conc (mg/)	Concm g/ml) *7.5	CDP	%CDP
10	0.042	0.043	0.042	0.817	10	0.008	0.06	0.06	4.68
20	0.05	0.044	0.044	0.896	10	0.089	0.67	0.06	5.34
30	0.051	0.052	0.051	1.174	10	0.011	0.08	0.16	12.7
40	0.09	0.059	0.059	1.472	10	0.014	0.11	0.27	21.1
50	0.062	0.062	0.062	1.591	10	0.015	0.11	0.40	30.6
60	0.069	0.069	0.069	1.869	10	0.018	0.13	0.5	41.3
70	0.074	0.07	0.072	1.988	10	0.019	0.14	0.69	53.4
80	0.083	0.082	0.082	2.404	10	0.024	0.18	0.87	67.0
90	0.087	0.089	0.088	2.623	10	0.026	0.19	1.08	82.5
100	0.102	0.103	0.102	3.198	10	0.031	0.23	1.30	100



Fig 8: Drug Permeated Study in Sodium Salicylate.

Percentage Cumulative Drug Permeated Study in Sodium Benzoate:

Table 4: Percentage Cumulative Drug Permeated Study in Sodium Benzoate.

Time (min)	Absorbance (nm)								
	A1	A2	Average	Conc (mcg/m)	D.F	Conc (mg/ml)	Conc (mg/ml)*7.5	CDP	%CDP
10	0.059	0.061	0.06	1.5119	10	0.015119	0.113392	0.11339	10.27
20	0.061	0.065	0.063	1.6309	10	0.016309	0.122321	0.12851	11.65
30	0.069	0.072	0.0705	1.9285	10	0.019285	0.144642	0.1599	14.49
40	0.077	0.079	0.078	2.2261	10	0.022261	0.166964	0.21065	19.09
50	0.082	0.084	0.083	2.4246	10	0.024246	0.181845	0.28363	25.71
60	0.095	0.095	0.095	2.9007	10	0.029007	0.217559	0.38085	34.52
80	0.107	0.107	0.107	3.3769	10	0.033769	0.25327	0.50708	45.96
100	0.119	0.118	0.1185	3.8333	10	0.038333	0.2875	0.66708	60.47
120	0.121	0.121	0.121	3.9325	10	0.039325	0.294946	0.86541	78.45
180	0.124	0.123	0.1235	4.0317	10	0.04031	0.302380	1.10307	100



Fig 9: Drug Permeated Study in Sodium Salicylate.

Comparison of dissolution profile in hydrotropic agents

Table 4: Comparative Study of CDP in different Hydrotropic Agents.

Time(min)	Drug	Drug: NA	Drug:SS	Drug:SB
0	0	0	0	0
10	0.013731	5.826923	4.713462	8.722527
20	0.152408	6.603846	5.341923	9.885531
30	0.2071	8.342308	12.86269	12.30311
40	0.277369	11.36538	21.28346	16.20421
50	0.5141	15.88077	30.835	21.81777
60	0.538292	22.07308	41.60962	29.2964
80	0.752369	30.12692	53.815	39.00641
100	0.907638	40.49615	67.54346	51.3141
120	1.038985	53.45769	83.11808	66.57051
180	1.245062	69.07308	100.7081	84.85195



Fig 10: Comparative study of %CDP of Desloratadine with Hydrotropic agents.

3.6 CONCLUSION

Solubility is the important parameter of the pharmacokinetic performance of any drug. There are primary issues of medications which are inadequately dissolvable in water and less bioavailable outcomes in restorative disappointment. Hydrotropic solubilization was observed to be great method in the dissolvability and disintegration improvement of poor water solvent medications. To upgrade the dissolvability of the Desloratadine tranquilize Hydrotropy strategy is utilized for improving the solvency of the inadequately solvent medications. The strategy can be utilized for the normal investigation of the medication. This strategy will have specific significance in detailing of fluid dose structures to give new life to old medications. Different ex-perimental studies have affirmed their solvency potential alongside a non-lethal, non-combustible and eco-accommodating nature.

Analytical Methods, calibration curve of the drug was done in 0.1N HCl, Methanol, and Methanol: Water. The λ_{max} of the drug Desloratadine was found to be in 200-300 range in aqueous standard plot of the drug.

From the consequences of softening point, UV Scan and FTIR, it might be reasoned that the medication is unadulterated and has no pollutions. The drug is efficient for the calculation of the solubility enhancement in various hydrotropic agents.

REFERENCES

1. K.A. khan the concept of dissolution efficiency. J. Pharm. Pharmacol., 1975; 27: 48-49. DOI: http://dx.doi.org/10.1111/j.2042-7158.1975.tb09378.x
2. Manivannan R, Parthiban KG, Balasubramaniam A, Joshi P, Senthilkumar N. Formulation Development and Evaluation of Desloratadine Tablet. Int J Pharm Tech Res, 2010; 2(3): 2101-2106.
3. Morissette SL, Almarsson Ö, Peterson ML, Remenar JF, Read MJ, Lemmo AV, et al. High-throughput crystallization: polymorphs, salts, cocrystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev, 2004; 56(3): 275-300.
4. Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res, 2008; 25(3): 530-541.
5. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev, 2004; 56(3): 335-347.
6. Huang, L.-F.; Tong, W.-Q. Impact of solid state properties on developability assessment of drug candidates. Advanced Drug Delivery Reviews, 2004; 56(3): 321-334.
7. Sun, C. C. Materials Science Tetrahedron—A Useful Tool for Pharmaceutical Research and Development. Journal of Pharmaceutical Sciences, 2009; 98(5): 1671-1687.
8. Joiris, E.; Martino, P. D.; Berneron, C.; Guyot-Hermann, A.-M.; Guyot, J.-C. Compression Behavior of Orthorhombic Paracetamol. Pharmaceutical Research, 1998; 15(7): 1122-1130.
9. Tye, C. K.; Sun, C.; Amidon, G. E. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. Journal of Pharmaceutical Sciences, 2005; 94(3): 465-472.
10. Rohrs, B. R.; Amidon, G. E.; Meury, R. H.; Secreast, P. J.; King, H. M.; Skoug, C. J. Particle Size Limits to Meet USP Content Uniformity Criteria for Tablets and Capsules. Journal of Pharmaceutical Sciences, 2006; 95(5): 1049-1059.7